NCT00742963 2025-05-13
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
ImmunoGenesis
Phase 1/2 Completed
Clinical Trials
11 trialsNCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT02342379 2020-04-10
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01403610 2019-07-24
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01485042 2017-09-01
PATH
Duke University
Phase 1 Completed
NCT01440088 2016-06-02
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Threshold Pharmaceuticals
Phase 3 Completed
NCT00743379 2015-05-07
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1/2 Completed
NCT01149915 2015-05-07
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
Phase 1 Completed
NCT00495144 2012-07-27
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Completed